Clinical trial Recruiting at 1 site Interventional Ages 0 Days to 24 Months

BioAmicus Complete for infants with colic, reflux, constipation, or loose stools (0–24 months)

Official title: Evaluation of the Efficacy and Safety of the Multistrain Probiotic "BioAmicus Complete" in Improving Gastrointestinal Symptoms in Children Aged 0-24 Months: A Randomized, Open-Label, Parallel-Group, Controlled Trial

Run by Haiphong University of Medicine and Pharmacy · NCT07148583 · Data updated 2026-11-12

This study will see if the multistrain probiotic BioAmicus Complete can help reduce caregiver‑reported tummy symptoms in infants aged 0–24 months.

Quick facts

Study typeInterventional
Ages0 Days to 24 Months
SexAll
Enrollment110 (estimated)
SponsorHaiphong University of Medicine and Pharmacy
Academic / other
Locations1 site (Haiphong, Hai Phong)
StatusRecruiting
StartedSeptember 5, 2025
Main results expectedApril 30, 2026
Study endsMay 30, 2026
Registry record updatedJanuary 29, 2026
Trial IDNCT07148583 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are infants aged 0–24 months with clinician‑assessed functional GI symptoms whose caregivers can provide consent, complete questionnaires/diaries, collect stool samples as requested, and avoid other probiotic products during the study.

Probably not a fit

Infants with major congenital gastrointestinal anomalies, chronic GI diseases requiring ongoing prescription therapy, known immunodeficiency or current immunosuppression, or clinically unstable severe illness are excluded and unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study randomizes infants with clinician‑assessed functional gastrointestinal symptoms to receive BioAmicus Complete or usual care and follows them over the study period to measure change in symptoms. The primary outcome is the change in Infant Gastrointestinal Symptom Questionnaire (IGSQ) total score from baseline to end of study. Secondary outcomes include symptom domains (colic/regurgitation, stool frequency and consistency), caregiver quality of life, growth, health care use and antibiotic exposure, and safety monitoring for adverse events. Stool samples will be collected for exploratory analysis of microbiome composition and diversity to explore biological changes associated with symptom changes.

Why it matters

Potential benefit: If successful, this could offer a safe, easy‑to‑use probiotic option to reduce infant gastrointestinal symptoms and lower caregiver burden.

How similar studies have gone: Some single‑strain probiotics have shown benefits for specific infant symptoms like colic or regurgitation in prior trials, but results are mixed and multistrain formulations such as BioAmicus Complete have not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 0-24 months at enrollment.
* Infant has clinician-assessed functional gastrointestinal symptoms (e.g., colic/irritability, regurgitation, constipation, loose stools), judged suitable for study participation.
* Parent or legal guardian provides written informed consent and agrees to comply with study procedures (questionnaires/diaries and sample collection, if applicable).
* Caregivers agree to avoid other probiotic products during the study period, except as directed by the study team.

Exclusion Criteria:

* Major congenital gastrointestinal anomalies or known chronic gastrointestinal diseases requiring ongoing prescription therapy (e.g., Hirschsprung disease, inflammatory bowel disease, short-bowel syndrome).
* Clinically unstable condition or severe/critical illness that could interfere with participation or safety in the opinion of the investigator.
* Known or suspected primary or secondary immunodeficiency, or current immunosuppressive therapy.
* History of severe allergy or hypersensitivity to components of the investigational product.
* Recent use of systemic antibiotics within 14 days prior to baseline, or use of probiotic supplements within 14 days prior to baseline (per protocol).
* Participation in another interventional clinical trial within 30 days prior to enrollment or during the study.
* Any condition that, in the investigator's judgment, would make the participant unsuitable for the study or confound outcome assessments.

Where it's running

  • Clinical Trial and Bioequivalence Center
    Haiphong, Hai Phong, Vietnam
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.